Boston Scientific to Adopt HRS Guidelines

NATICK, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it plans to adopt the recommendations announced today by the Heart Rhythm Society (HRS) Task Force on medical device performance policies and guidelines. The Company issued the following statement:

"Boston Scientific continues to support and commend the Heart Rhythm Society (HRS) for the development of guidelines regarding device performance. We continue to believe these guidelines are in the best interest of patients and physicians, and we plan to adopt them.

We plan to implement additional changes consistent with HRS guidelines, continuing our commitment to best facilitate patient care with safe and reliable therapy. This includes our commitment to the development of independent, industry-wide oversight to facilitate consistent communications, surveillance and product performance reporting practices.

Boston Scientific CRM has implemented industry-leading systems and practices consistent with the guidelines, for example:

  * The industry-leading Boston Scientific CRM Product Performance Report
    clearly demonstrates our commitment to timely and responsible
    communication. The CRM Product Performance Report (PPR) is published
    quarterly. Our monthly CRM Product News supplements the quarterly PPR,
    highlighting information related to our products and therapies. Both
    the CRM Product Performance Report and the CRM Product News can be
    easily accessed either by subscription or online at

  * Boston Scientific's LATITUDE® Patient Management System is the only
    wireless and remote patient management system that meets both Heart
    Rhythm Society Guidelines for automatic device surveillance and
    American College of Cardiology/American Heart Association Guidelines
    for monitoring weight, activities of daily living and blood pressure."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

  CONTACT:  Milan Kofol
            Investor Relations
            Boston Scientific Corporation

            Paul Donovan
            Media Relations
            Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Milan Kofol of Investor Relations, +1-508-650-8569, or Paul
Donovan, Media Relations, +1-508-650-8541, both of Boston Scientific

Web site: